Toxicology

7
Jun

WEBINAR #5 Naked Immunology – Epithelial Barrier Theory – Cezmi Akdis

Top-level science through the eyes of an expert.The fifth Webinar. This webinar episode is open to English-speaking participants with a solid scientific background. Featured speaker is Dr. Cezmi Akdis, the director of the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos and Professor in Zurich University Medical Faculty. In this webinar, Dr. Akdis will focus on the effects
Read more
25
Apr

Why testing and mitigating Injection Site Reactions is critical during drugs/vaccines development ?

Why testing & mitigating Injection Site Reactions is critical during drugs/vaccines development? Injection site reactions (ISR) are a common occurrence when a person receives an injection in the skin, such as a vaccine or self-administered biologics.These reactions occur due to the activation of the immune system at the injection site. When a foreign substance, such as a vaccine or medication,
Read more
6
Jul

PRESS RELEASE – Genoskin launches the ISR platform®

Genoskin announces the launch of the ISR platform®, a new pre-clinical toolbox designed to study injection site reactions (ISR) in humans ahead of clinical trials.

22
Feb

Using NativeSkin® to study poison ivy-induced dermatitis

Using NativeSkin® to evaluate poison ivy effects  A couple of months ago, Genoskin’s team started to wonder: “Why not try to better understand poison ivy dermatitis through our NativeSkin® model ?” In this article, we summarize information about what is known regarding the poison ivy reaction and what happens on a macroscopic level when poison ivy toxin is applied to
Read more
13
Mar

Genoskin supports CoViD19 research!

Genoskin COVID-19 research preferred access program On Friday, March 13th 2020, Genoskin launched a preferred access program for all research teams actively developing therapeutic and vaccine technologies for the COVID-19 pandemic. The World Health Organization (WHO) officially declared on March 11th, the outbreak of COVID-19 a pandemic. The disease caused by SARS-CoV-2 has spread globally. Over 130,000 individuals are affected so

Read more

25
Oct

Genoskin granted new patent on subcutaneous injection model

Genoskin granted a new patent on ex vivo subcutaneous injection model The French National Institute for Intellectual Property (INPI) granted Genoskin's latest patent on its unique ex vivo subcutaneous injection model, HypoSkin®. A boom in the subcutaneous biologics market Today, subcutaneous injection is one of the most common methods to deliver a drug into the human body. Its use has increased significantly
Read more